Chimeric antigen receptor

A chimeric antigen receptor, antigen technology, applied in the direction of antibodies, antibody medical components, antibody mimetics/scaffolds, etc., can solve the problems of solid tumors that have not been shown to be effective

Active Publication Date: 2019-11-15
NOILE IMMUNE BIOTECH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the current situation is that cancer immunotherapy using CAR-T cells has achieved effective results only for malignant tumors of hematopoietic organs, and no results showing effectiveness have been obtained for solid tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor
  • Chimeric antigen receptor
  • Chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0251] [Example 1] Production of anti-GM2 CAR expressing T cells expressing IL-7 and CCL19 (selection of immune function promoting factors of T cells)

[0252] There are at least several hundred kinds of molecules capable of controlling the functions of T cells in the living body. The present inventors selected IL-7 and CCL19 as immune function promoting factors for improving the anti-tumor effect in CAR-T cells from a huge combination.

[0253] It should be noted that the aforementioned IL-7 is a cytokine necessary for the survival of T cells, and is produced by non-hematopoietic cells such as stromal cells present in bone marrow, thymus, and lymphoid organ tissues. On the other hand, almost no IL-7 producing ability was found in T cells.

[0254] In addition, the above-mentioned CCL19 is mainly produced by dendritic cells or macrophages in lymph nodes, and has a function of inducing the migration of T cells, B cells, and mature dendritic cells via CCR7 as its receptor.

[...

Embodiment 2

[0267] [Example 2] CAR expression measurement by flow cytometry (flow cytometry analysis)

[0268] Analysis of the expression level of CAR that recognizes GM2 as an antigen was performed by two-color flow cytometry analysis. The prepared anti-GM2 CAR-IL-7 / CCL19-expressing T cells were mixed with biotinylated protein L (manufactured by GenScript), allophycocyanin (APC)-labeled streptavidin (manufactured by Affymetrix), and APC-labeled Anti-CD8 monoclonal antibody (manufactured by Affymetrix) was reacted for staining. EC800 (manufactured by Sony Corporation) was used for the flow cytometer, and FlowJo software (manufactured by Tree Star Corporation) was used for data analysis.

[0269] show the result in figure 2 . The left picture shows cells without CAR gene introduction, and the right picture shows the results of anti-GM2 CAR-IL-7 / CCL19 expressing T cells. In addition, the numerical value in a figure shows the percentage of each population. Such as figure 2 As shown, ...

Embodiment 3

[0270] [Example 3] Production of IL-7 and CCL19

[0271] (Determination of IL-7 and CCL19 concentrations in the culture supernatant of anti-GM2 CAR-IL-7 / CCL19 expressing T cells)

[0272] The culture supernatant of anti-GM2 CAR-IL-7 / CCL19 expressing T cells or non-gene-introduced cells on the 7th day of the above-mentioned culture was recovered, and commercially available ELISA kits (manufactured by Peprotech and R&D systems, respectively) were used to detect the The production of IL-7 and CCL19 by anti-GM2 CAR-IL-7 / CCL19 expressing T cells was investigated.

[0273] [result]

[0274] The results are shown in image 3 . Such as image 3 As shown, in the culture supernatant (GM2CAR) of anti-GM2 CAR-IL-7 / CCL19 expressing T cells, IL-7 was detected to be more than 300 pg / ml, and CCL19 was detected to be more than 2000 pg / ml. From these results, it was confirmed that the anti-GM2CAR-IL-7 / CCL19-expressing T cells expressed IL-7 and CCL19, and the expressed IL-7 and CCL19 were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A chimeric antigen receptor containing a target antigen binding domain, a transmembrane domain and a T cell activation signal transduction domain, wherein the target antigen is ganglioside GM2.

Description

technical field [0001] The present invention relates to a chimeric antigen receptor, a cell expressing the chimeric antigen receptor, a vector containing a base sequence encoding the chimeric antigen receptor, and the like. [0002] This application claims priority based on Japanese Patent Application No. 2017-061461 filed in Japan on March 27, 2017, the contents of which are incorporated herein. Background technique [0003] A chimeric antigen receptor (Chimeric Antigen Receptor: hereinafter also referred to as "CAR") is an artificial chimeric protein obtained by fusing a single-chain antibody that recognizes a cell surface antigen of a cancer cell with a signaling region that induces activation of T cells. For example, by introducing a gene encoding CAR into normal peripheral blood T cells (peripheral blood T lymphocytes) that do not have tumor reactivity, CAR-expressing T cells capable of expressing CAR (hereinafter also referred to as "CAR-T cells") can be produced in la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K35/17A61P35/00C07K16/18C12N5/10C12N15/62
CPCA61K35/17A61P35/00C07K14/7051C07K16/3084A61K39/001171A61K2039/5156A61K2039/5158C12N2510/00C12N5/0636C07K2317/622A61K2039/505C07K2319/33C07K2319/03C07K16/2887C07K2317/21C12N2501/515C12N2502/30C12N2501/2307C07K14/705C07K16/44C07K2319/00C07K14/52C12N15/63C07K14/5418
Inventor 玉田耕治佐古田幸美石崎秀信
Owner NOILE IMMUNE BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap